A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Clinical trial NCT05399654 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05399654
- Sponsor
- Tallac Therapeutics
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-28
- Primary completion
- 2026-01-27
- Enrollment
- 72
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.